To describe oncological outcomes after progressive site‐directed therapy (PSDT) in genuine and induced oligometasatic (OM)‐castration‐resistant prostate cancer (CRPC). Click to show full abstract
To describe oncological outcomes after progressive site‐directed therapy (PSDT) in genuine and induced oligometasatic (OM)‐castration‐resistant prostate cancer (CRPC).
               
Click one of the above tabs to view related content.